Company announcement - Announcements and Circulars - Investor - XZenith Biopharm

Investor relations

Company announcement Performance presentation

Performance promotion

Company announcement

All

VOLUNTARY ANNOUNCEMENT COMPLETION OF ENROLLMENT OF ALL SUBJECTS IN PHASE III CLINICAL TRIAL IN CHINA OF ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS (AN JIU WEI) FOR THE TREATMENT OF REFLUX ESOPHAGITIS
DATE OF BOARD MEETING
VOLUNTARY ANNOUNCEMENT INCLUSION OF THE SHARES OF THE COMPANY IN STOCK LIST OF HONG KONG STOCK CONNECT
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2026
VOLUNTARY ANNOUNCEMENT MARKETING APPROVAL FOR THE THIRD INDICATION OF XUANYUENING (BIREOCICLIB TABLETS) FOR THE FIRST-LINE TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER GRANTED BY THE NMPA
VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2026
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2025
List of Directors and their Role and Function
APPOINTMENT OF GENERAL MANAGER

<1 2 3 4 5 6 >